Israeli new shekel

Ellomay Capital Reports Results for the Fourth Quarter and Full Year of 2023

Retrieved on: 
Sunday, March 31, 2024
Shekel, Season, Tax, Agreement, Dorad Power Station, SWAP, Sale, P-50, Depreciation, Disclosure, Bank statement, RDL, Electricity, Klahim, Legislation, AMPA, Iron, Public expenditure, Good, Israeli new shekel, PPA, Zorlu, Komemiyut, Bank Mizrahi-Tefahot, Acquisition, PV, EBIDTA, Loss, D&O, Greenhouse, Government, Total, Renewable energy

•  Operating expenses were approximately €22.9 million for the year ended December 31, 2023, compared to approximately €23.7 million for the year ended December 31, 2022.

Key Points: 
  • •  Operating expenses were approximately €22.9 million for the year ended December 31, 2023, compared to approximately €23.7 million for the year ended December 31, 2022.
  • •  Project development costs were approximately €4.5 million for the year ended December 31, 2023, compared to approximately €3.8 million for the year ended December 31, 2022.
  • During 2023, the Ellomay Solar project (28 MW) produced revenues from the sale of electricity and green certificates of approximately €4 million.
  • The Company's EBITDA may not be indicative of the Company's historic operating results; nor is it meant to be predictive of potential future results.

Evogene Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
Shekel, Growth, Sale, Perception, Health, Webcast, Fruit, Herbicide, AG, Generator, CFIA, Marketing, Seed, Canadian Food Inspection Agency, CPB, Therapy, Production, ICL, Burn, Conference, Safety, Collaboration, Patent, CO2, Agreement, Insurance, Visceral pain, Agricultural science, Gene editing, EIC, Probiotic, Computational biology, Patient, Israeli new shekel, IBS, Pharmaceutical industry

REHOVOT, Israel, March 7, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced its financial results for the fourth quarter and full-year period ending December 31, 2023.

Key Points: 
  • Collaboration with Colors Farm and Ben Gurion University: Evogene partnered to pioneer crustacean gene editing technology aimed at enhancing crustacean traits.
  • EU Grant for Ag-Seed Division: Evogene secured a €1.2 million EU grant to develop oil-seed crops with enhanced CO2 assimilation and drought tolerance.
  • In the fourth quarter of 2023, general and administrative expenses were approximately $1.2 million, down from about $1.7 million in the same period the previous year.
  • This increase in net loss during the fourth quarter of 2023 is primarily attributed to other income received in 2022, as mentioned above.

VBI Vaccines Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, Shekel, MLE, High-net-worth individual, Hepatitis B vaccine, GMT, HBsAg, Net, AASLD, Bank statement, Disease, GBM, Government, Administration, Patient, HBV, Research and development, Prison, Allergy, Fast track (FDA), Autoimmune disease, InSight, Liver, VBI, Messenger, Internationalized domain name, GAAP, Vaccine, Cancer, Partnership, R, Seroconversion, Growth, Infection, Israeli new shekel, Pharmaceutical industry, Video game, Rare-earth element, Cryptocurrency, Bank

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023.
  • Cost of Revenues: Cost of revenues was $2.5 million in the third quarter of 2023 as compared to $2.7 million in the third quarter of 2022.
  • Research and Development (R&D): R&D expenses for the third quarter of 2023 were $1.5 million as compared to $5.0 million for the third quarter of 2022.
  • Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

Ellomay Capital Reports Results for the Three and Six Months Ended June 30, 2023

Retrieved on: 
Thursday, September 28, 2023
Shekel, Maintenance, Zorlu, Sale, Sharsheret, D&O, Electricity, Bank statement, Tax, Battery, Season, Bank Mizrahi-Tefahot, P-50, Talmei Yosef, RDL, PV, Israeli new shekel, Government, Kilowatt-hour, Public expenditure, Komemiyut, EBITDA, TASE, Depreciation, NIS, Dunam, PPA, Greenhouse, NYSE, Manara, Legislation, Klahim, Renewable energy, Cryptocurrency, Spanish, Dorad Power Station

Revenues were approximately €25.5 million for the six months ended June 30, 2023, compared to approximately €29.2 million for the six months ended June 30, 2022.

Key Points: 
  • Revenues were approximately €25.5 million for the six months ended June 30, 2023, compared to approximately €29.2 million for the six months ended June 30, 2022.
  • Operating expenses were approximately €12 million for the six months ended June 30, 2023, compared to approximately €13.1 million for the six months ended June 30, 2022.
  • General and administrative expenses were approximately €2.9 million for the six months ended June 30, 2023, compared to approximately €3.3 million for the six months ended June 30, 2022.
  • Profit for the six months ended June 30, 2023, was approximately €4.6 million, compared to a loss of approximately €0.6 million for the six months ended June 30, 2022.

VBI Vaccines Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shekel, Vaccine, Impairment, Prison, Medicaid, Partnership, SG, GBM, CPT, Marketing, NRC, SARS-CoV-2, Bank statement, COVID-19, Net, SARS, Hepatitis B, Hepatitis B vaccine, GAAP, MERS-related coronavirus, VBI, Israeli new shekel, Government, Fast track (FDA), CDC, High-net-worth individual, Medicare, Research and development, MERS, ...Continued, Anthrax Vaccine Immunization Program, ISED, Patient, Administration, Recombinant, InSight, Growth, Internationalized domain name, R, Syneos Health, HBV, National Research Council, Disease, Pharmaceutical industry, Video game, Bank, Adsorption

Cost of Revenues: Cost of revenues was $3.5 million in the second quarter of 2023 as compared to $2.5 million in the second quarter of 2022.

Key Points: 
  • Cost of Revenues: Cost of revenues was $3.5 million in the second quarter of 2023 as compared to $2.5 million in the second quarter of 2022.
  • Research and Development (R&D): R&D expenses for the second quarter of 2023 were $3.3 million as compared to $5.6 million for the second quarter of 2022.
  • Impairment for the second quarter of 2023 was $20.0 million as compared to $0 for the second quarter of 2022.
  • Foreign exchange loss for the second quarter of 2023 was $5.9 million as compared to $21.9 million for the second quarter of 2022.

Ellomay Capital Reports Results for the Three Months Ended March 31, 2023

Retrieved on: 
Thursday, June 29, 2023
Shekel, Sharsheret, Electricity, Tax, Battery, Bank Mizrahi-Tefahot, P-50, Talmei Yosef, AMPA, Israeli new shekel, PV, Government, Kilowatt-hour, Sale, Public expenditure, Komemiyut, EBITDA, GGB, TASE, Depreciation, NIS, Dunam, Heat, PPA, Greenhouse, Three Months, NYSE, Manara, Legislation, Renewable energy, Cryptocurrency, Video game, Spanish, Dorad Power Station, Klahim

Operating expenses were approximately €6.5 million for the three months ended March 31, 2023, compared to approximately €6 million for the three months ended March 31, 2022.

Key Points: 
  • Operating expenses were approximately €6.5 million for the three months ended March 31, 2023, compared to approximately €6 million for the three months ended March 31, 2022.
  • Depreciation expenses were approximately €4.1 million for the three months ended March 31, 2023, compared to approximately €4 million for the three months ended March 31, 2022.
  • Net profit was approximately €2.8 million for the three months ended March 31, 2023, compared to net loss of approximately €3.4 million for the three months ended March 31, 2022.
  • EBITDA was approximately €3.6 million for the three months ended March 31, 2023, compared to approximately €3.8 million for the three months ended March 31, 2022.

Microbot Medical Receives a Non-Dilutive Grant from The Israel Innovation Authority Supporting the Development of the Manufacturing Process for its Endovascular Surgical Robotic System

Retrieved on: 
Friday, June 2, 2023
Shekel, Libor, ZEUS robotic surgical system, IIA, Element, Israeli new shekel, Israel Innovation Authority, NIS, 3D printing, Pharmaceutical industry

“This non-dilutive grant will facilitate our efforts to establish the manufacturing infrastructure capability for the LIBERTY® system.

Key Points: 
  • “This non-dilutive grant will facilitate our efforts to establish the manufacturing infrastructure capability for the LIBERTY® system.
  • While we will work with manufacturing partners to scale production, the sophisticated and crucial core technology and elements of the manufacturing process are expected to be handled internally.
  • In relation to the IIA grant, Microbot is obligated to pay royalties amounting to between 3%-5% of its future sales of the LIBERTY product up to the grant amount plus interest.
  • The grant is linked to the U.S. dollar and bears interest at Libor per annum.

VBI Vaccines Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shekel, Insurance, Medicaid, Vaccination, Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, GBM, CPT, SG, SARS-CoV-2, Bank statement, COVID-19, Net, SARS, Hope, Hepatitis B, GAAP, Hepatitis B vaccine, MERS-related coronavirus, Costco, VBI, Israeli new shekel, Government, Individual savings account, Medicare, Research and development, Hepatitis, MERS, Walmart, Patient, Administration, Access, Recombinant, Antibody, InSight, Federal Bureau of Prisons, Growth, U.S. Department of Veterans Affairs, Office of Inspector General, Rite Aid, Internationalized domain name, Vaccine, R, HBV, Disease, Corporate development, Pharmaceutical industry, Health insurance, Rare-earth element, Management, Video game, Financial services, Adsorption, Prison

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023.
  • Cash Position: VBI ended the first quarter of 2023 with $40.4 million in cash as compared with $62.6 million in cash as of December 31, 2022.
  • Cost of Revenues: Cost of revenues was $3.6 million in the first quarter of 2023 as compared to $2.8 million in the first quarter of 2022.
  • Foreign exchange loss for the first quarter 2023 was $6.8 million as compared to a loss of $4.4 million for the first quarter of 2022.

Ellomay Capital Reports Results for the Fourth Quarter and Full Year of 2022

Retrieved on: 
Friday, March 31, 2023
Shekel, Tax, Equipment, Market access, Operation, Radiation, IAS 16, Sharsheret, Bank statement, Construction, Electricity, Bank Mizrahi-Tefahot, P-50, Income tax, Talmei Yosef, CHP, AMPA, Local Democracy, Economic Development and Construction Act 2009, Israeli new shekel, PV, Minerals Management Service, Sale, Public expenditure, Komemiyut, EBITDA, PAC, TASE, Depreciation, NIS, Dunam, Heat, Transport, IAS, PPA, Greenhouse, NYSE, Manara, Legislation, Klahim, Cryptocurrency, Renewable energy, Airline, Natural gas, Oil, Spanish, Dorad Power Station

The increase in depreciation and amortization expenses is mainly attributable to the commencement of recognition of results of Ellomay Solar upon connection to the Spanish grid in June 2022.

Key Points: 
  • The increase in depreciation and amortization expenses is mainly attributable to the commencement of recognition of results of Ellomay Solar upon connection to the Spanish grid in June 2022.
  • The average electricity price in Spain during the fourth quarter of 2022 was approximately €0.11/kWh, compared to an average price of €0.20/kWh during 2021.
  • Due to lower radiation during the fourth quarter of 2022, the electricity produced by the Talasol PV Plant was lower by approximately 24,000 MW compared to the fourth quarter of 2021.
  • Commencing the third quarter of 2022, this PV plant operated at full capacity and generated revenues of approximately €3.6 million during 2022.

VBI Vaccines Reports Full Year 2022 Financial Results

Retrieved on: 
Monday, March 13, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, Momentum, Shekel, Disease, Israeli new shekel, Vaccine, CEPI, SARS, United Kingdom, Prescription Drug User Fee Act, Hepatitis B, Hepatitis B vaccine, Medicare, GAAP, Medicaid, Net, Fast track (FDA), Coronavirus, SARS-CoV-2, HBsAg, InSight, Glioblastoma, Acquisition, Insurance, Patient, Week, GBM, Variants of SARS-CoV-2, VBI, Bank statement, MERS, Small RNA, MERS-related coronavirus, Individual development account, Government, Growth, R, Research and development, Phase, Public, HBV, Administration, Partnership, Survival, Pharmaceutical industry, Financial services, Valneva SE

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2022.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2022.
  • Revenues, net: Revenues, net for the full year 2022 were $1.1 million, compared to $0.6 million for the same period in 2021.
  • Certain intercompany loans between VBI Vaccines Inc. and our subsidiaries are denominated in a currency other than the functional currency of each entity.
  • Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.